PYXS

Pyxis Oncology Inc

PYXS, USA

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

https://www.pyxisoncology.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PYXS
stock
PYXS

3 Promising Penny Stocks With Over $90M Market Cap simplywall.st

Read more →
PYXS
stock
PYXS

How Low Can Pyxis Oncology Stock Really Go? Trefis

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$7.675

Analyst Picks

Strong Buy

4

Buy

2

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

4.01

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-31.99 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-20.84 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

High

0.54

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 46.64% of the total shares of Pyxis Oncology Inc

1.

Pfizer Inc

(11.3399%)

since

2025/06/30

2.

LAURION CAPITAL MANAGEMENT LP

(5.8466%)

since

2025/06/30

3.

Millennium Management LLC

(5.7078%)

since

2025/06/30

4.

TANG CAPITAL MANAGEMENT LLC

(4.0311%)

since

2025/06/30

5.

Vanguard Group Inc

(3.4658%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(2.0429%)

since

2025/07/31

7.

Palo Alto Investors, LLC

(1.6728%)

since

2025/06/30

8.

BlackRock Inc

(1.4944%)

since

2025/06/30

9.

Aberdeen Group PLC

(1.4722%)

since

2025/06/30

10.

683 Capital Management LLC

(0.8788%)

since

2025/06/30

11.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8672%)

since

2025/07/31

12.

Geode Capital Management, LLC

(0.8239%)

since

2025/06/30

13.

Renaissance Technologies Corp

(0.6737%)

since

2025/06/30

14.

UBS Group AG

(0.6387%)

since

2025/06/30

15.

PIER 88 INVESTMENT PARTNERS LLC

(0.592%)

since

2025/06/30

16.

Jane Street Group LLC

(0.5419%)

since

2025/06/30

17.

Decheng Capital LLC

(0.527%)

since

2025/06/30

18.

Schulhoff & CO Inc

(0.4434%)

since

2025/06/30

19.

iShares Biotechnology ETF

(0.4386%)

since

2025/08/31

20.

Fidelity Extended Market Index

(0.3978%)

since

2025/07/31

21.

Goldman Sachs Group Inc

(0.3616%)

since

2025/06/30

22.

State Street Corp

(0.3%)

since

2025/06/30

23.

Bank of New York Mellon Corp

(0.2661%)

since

2025/06/30

24.

Morgan Stanley - Brokerage Accounts

(0.2583%)

since

2025/06/30

25.

Bridgeway Ultra-Small Company Market

(0.2049%)

since

2025/06/30

26.

iShares Micro-Cap ETF

(0.172%)

since

2025/08/31

27.

Extended Equity Market Fund K

(0.1682%)

since

2025/06/30

28.

Fidelity Total Market Index

(0.1331%)

since

2025/07/31

29.

Fidelity Series Total Market Index

(0.1025%)

since

2025/07/31

30.

Spartan Extended Market Index Pool F

(0.095%)

since

2025/07/31

31.

NT Ext Equity Mkt Idx Fd - L

(0.0919%)

since

2025/06/30

32.

Northern Trust Extended Eq Market Idx

(0.0919%)

since

2025/06/30

33.

NT Col R2000 Val Idx Fd -DC -L -TierFour

(0.0881%)

since

2025/03/31

34.

HBM Healthcare Investments AG Ord

(0.0826%)

since

2025/06/30

35.

NT Ext Equity Mkt Idx Fd - NL

(0.0678%)

since

2025/06/30

36.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0526%)

since

2025/06/30

37.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0518%)

since

2024/12/31

38.

Vanguard Instl Ttl Stk Mkt Idx InstlPls

(0.0518%)

since

2025/07/31

39.

iShares Nasdaq US Biotech ETF USD Acc

(0.0507%)

since

2025/08/31

40.

Fidelity Nasdaq Composite Index

(0.0486%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.3213

Latest Release

Date

2025-09-30

EPS Actual

-0.35

EPS Estimate

-0.34

EPS Difference

-0.01

Surprise Percent

-2.9412%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.